Jiangxi Institute of Biological Products Inc.

江西生物制品研究所股份有限公司

06915.HK

Develops and produces human antiserum biological products, including the largest human tetanus antitoxin supply in China, for passive immunization against tetanus, snakebite envenoming and rabies; also the largest exporter of human TAT in China per Frost & Sullivan.

Filings

The documents are on HKEXnews; we link to the originals.

Matters the filing discloses

From the company’s latest filing; open a kind of matter to see how other companies disclosed it.

• Customer concentration
• Supplier concentration
• Connected or related major customers / suppliers
• Distribution model
• Reliance on platforms, partners or licences
• Single product, business line or region
• Government or SOE customers and tenders
• Raw material and commodity prices
• Pricing policy and price changes
• Outsourced production (OEM / contract manufacturing)
• Overseas markets and operations
• Particular sales arrangements
• Business changes and acquisitions
• Working capital: receivables, prepayments and cash cycle
• Inventory level and ageing
• Adverse change after the track record
• Non-IFRS measures and adjustments
• Related-party transactions and balances
• Other